Pub Date : 2024-08-01Epub Date: 2024-02-13DOI: 10.1007/s00595-024-02792-3
Kazuya Ise, Hisateru Tachimori, Jun Fujishiro, Hirofumi Tomita, Kan Suzuki, Hiroyuki Yamamoto, Hiroaki Miyata, Yasushi Fuchimoto
Purpose: The coronavirus disease 2019 (COVID-19) pandemic limited the delivery of medical resources. Although surgeries are triaged according to disease severity and urgency, a delay in diagnosis and surgery can be detrimental. We conducted this study to analyze data on the impact of the COVID-19 pandemic on pediatric surgery for different diseases or disorders.
Methods: We compiled and compared data on pediatric surgical cases from 2018 to 2020, using the National Clinical Database. The number of diseases, severity, complication rates, mortality rates by disease/disorder, and the COVID-19 pandemic areas were analyzed.
Results: The total number of cases of pediatric surgery in 2018, 2019, and 2020 was 50,026, 49,794, and 45,621, respectively, reflecting an 8.8% decrease in 2020 from 2018 and an 8.4% decrease in 2020 from 2019. A decrease was observed when the number of patients with COVID-19 was high and was greater in areas with a low infection rate. There was a marked decrease in the number of inguinal hernia cases. The number of emergency room visits and emergency surgeries decreased, but their relative proportions increased.
Conclusions: The COVID-19 pandemic decreased the number of pediatric surgeries, reflecting the limitations of scheduled surgeries and infection control measures.
{"title":"Impact of the novel coronavirus infection on pediatric surgery: an analysis of data from the National Clinical Database.","authors":"Kazuya Ise, Hisateru Tachimori, Jun Fujishiro, Hirofumi Tomita, Kan Suzuki, Hiroyuki Yamamoto, Hiroaki Miyata, Yasushi Fuchimoto","doi":"10.1007/s00595-024-02792-3","DOIUrl":"10.1007/s00595-024-02792-3","url":null,"abstract":"<p><strong>Purpose: </strong>The coronavirus disease 2019 (COVID-19) pandemic limited the delivery of medical resources. Although surgeries are triaged according to disease severity and urgency, a delay in diagnosis and surgery can be detrimental. We conducted this study to analyze data on the impact of the COVID-19 pandemic on pediatric surgery for different diseases or disorders.</p><p><strong>Methods: </strong>We compiled and compared data on pediatric surgical cases from 2018 to 2020, using the National Clinical Database. The number of diseases, severity, complication rates, mortality rates by disease/disorder, and the COVID-19 pandemic areas were analyzed.</p><p><strong>Results: </strong>The total number of cases of pediatric surgery in 2018, 2019, and 2020 was 50,026, 49,794, and 45,621, respectively, reflecting an 8.8% decrease in 2020 from 2018 and an 8.4% decrease in 2020 from 2019. A decrease was observed when the number of patients with COVID-19 was high and was greater in areas with a low infection rate. There was a marked decrease in the number of inguinal hernia cases. The number of emergency room visits and emergency surgeries decreased, but their relative proportions increased.</p><p><strong>Conclusions: </strong>The COVID-19 pandemic decreased the number of pediatric surgeries, reflecting the limitations of scheduled surgeries and infection control measures.</p>","PeriodicalId":22163,"journal":{"name":"Surgery Today","volume":" ","pages":"847-856"},"PeriodicalIF":1.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11266367/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139724089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: We aimed to investigate the POAF rate and blood FABP4 levels after perioperative L-carnitine administration in patients with esophageal cancer.
Methods: L-carnitine (3 g in three divided doses) was administered to 15 patients 2 days before and 3 days after surgery. POAF during the study period and blood FABP4 levels (ELISA) before and after L-carnitine administration were evaluated. Accurate 95% confidence intervals (CI) for POAF incidence and changes in blood FABP4 levels were calculated. The preoperative predicted POAF rate was calculated using an application for esophageal cancer. The correlation between FABP4 levels and the predicted POAF rate was analyzed using Pearson's coefficient (r).
Results: Thirteen patients completed this study. The predicted POAF rate was 24% (17%, 34%) (median; interquartile range). The actual incidence of POAF was 7.7% (95% CI: 0.2-36%). Blood FABP4 levels changed from 10.3 to 7.0 ng/mL; the average change was - 3.3 (95% CI: - 6.6 to - 0.1). A positive correlation was found between preoperative FABP4 levels and the predicted POAF rates (r = 0.564).
Conclusions: The POAF rate after esophageal surgery was 7.7% for L-carnitine. L-carnitine may reduce blood FABP4 levels. This preliminary study will contribute to the planning of sample sizes in future randomized trials.
{"title":"Incidence of atrial fibrillation after esophageal cancer surgery with L-carnitine use: a preliminary single-group interventional study.","authors":"Yasushige Shingu, Isao Yokota, Toshiaki Shichinohe, Soichi Murakami, Yuma Ebihara, Yo Kurashima, Satoshi Hirano, Satoru Wakasa","doi":"10.1007/s00595-024-02802-4","DOIUrl":"10.1007/s00595-024-02802-4","url":null,"abstract":"<p><strong>Purpose: </strong>We aimed to investigate the POAF rate and blood FABP4 levels after perioperative L-carnitine administration in patients with esophageal cancer.</p><p><strong>Methods: </strong>L-carnitine (3 g in three divided doses) was administered to 15 patients 2 days before and 3 days after surgery. POAF during the study period and blood FABP4 levels (ELISA) before and after L-carnitine administration were evaluated. Accurate 95% confidence intervals (CI) for POAF incidence and changes in blood FABP4 levels were calculated. The preoperative predicted POAF rate was calculated using an application for esophageal cancer. The correlation between FABP4 levels and the predicted POAF rate was analyzed using Pearson's coefficient (r).</p><p><strong>Results: </strong>Thirteen patients completed this study. The predicted POAF rate was 24% (17%, 34%) (median; interquartile range). The actual incidence of POAF was 7.7% (95% CI: 0.2-36%). Blood FABP4 levels changed from 10.3 to 7.0 ng/mL; the average change was - 3.3 (95% CI: - 6.6 to - 0.1). A positive correlation was found between preoperative FABP4 levels and the predicted POAF rates (r = 0.564).</p><p><strong>Conclusions: </strong>The POAF rate after esophageal surgery was 7.7% for L-carnitine. L-carnitine may reduce blood FABP4 levels. This preliminary study will contribute to the planning of sample sizes in future randomized trials.</p>","PeriodicalId":22163,"journal":{"name":"Surgery Today","volume":" ","pages":"892-898"},"PeriodicalIF":1.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139932891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: We evaluated the surgical outcomes of salvage extended surgery after definitive medical treatment with an immune-checkpoint inhibitor (ICI) for locally advanced or unresectable non-small-cell lung cancer (NSCLC).
Methods: The subjects of this single-center retrospective analysis were 14 patients who underwent salvage surgery after ICI treatment between May, 2017 and April, 2023 at our institute. We reviewed the comprehensive surgical outcomes, including operative procedures, intraoperative findings, and postoperative morbidities. Overall survival (OS) was calculated using a Kaplan-Meier estimation.
Results: The initial clinical stage before medical treatment (c-stage) was stage III in eight patients, stage IV in five patients, and one patient had postoperative lung cancer recurrence. The indications for surgery were as follows: local control for relapse or residual tumor in ten patients and discontinuation of systemic therapy because of treatment-related complications in four patients. The surgical modes were segmentectomy (n = 1), lobectomy (n = 4), bilobectomy (n = 3), pneumonectomy (n = 6), and bronchoplasty (n = 7). Grade 3 or higher postoperative morbidities were observed in six patients, including only one case of 90-day mortality.
Conclusions: Our series demonstrated that the surgical outcome of salvage extended surgery after ICI therapy may be positive with careful selection of the procedure and indication.
目的:我们评估了使用免疫检查点抑制剂(ICI)对局部晚期或不可切除的非小细胞肺癌(NSCLC)进行明确内科治疗后进行挽救性扩大手术的手术效果:本单中心回顾性分析的对象是2017年5月至2023年4月期间在我院接受ICI治疗后接受挽救手术的14例患者。我们回顾了综合手术结果,包括手术过程、术中发现和术后发病情况。采用Kaplan-Meier估计法计算总生存率(OS):结果:8 名患者接受药物治疗前的初始临床分期(c 期)为 III 期,5 名患者为 IV 期,1 名患者术后肺癌复发。手术指征如下:10 例患者因复发或残留肿瘤而进行局部控制,4 例患者因治疗相关并发症而停止全身治疗。手术方式包括肺段切除术(1例)、肺叶切除术(4例)、双肺叶切除术(3例)、肺切除术(6例)和支气管成形术(7例)。6例患者术后出现3级或更高的发病率,其中只有1例患者出现90天死亡:我们的系列研究表明,在 ICI 治疗后进行抢救性扩大手术,只要谨慎选择手术方式和适应症,手术效果可能会很好。
{"title":"Salvage extended surgery after immune-checkpoint inhibitor treatment for advanced non-small cell lung cancer.","authors":"Eisuke Goto, Aritoshi Hattori, Mariko Fukui, Takeshi Matsunaga, Kazuya Takamochi, Kenji Suzuki","doi":"10.1007/s00595-024-02812-2","DOIUrl":"10.1007/s00595-024-02812-2","url":null,"abstract":"<p><strong>Purpose: </strong>We evaluated the surgical outcomes of salvage extended surgery after definitive medical treatment with an immune-checkpoint inhibitor (ICI) for locally advanced or unresectable non-small-cell lung cancer (NSCLC).</p><p><strong>Methods: </strong>The subjects of this single-center retrospective analysis were 14 patients who underwent salvage surgery after ICI treatment between May, 2017 and April, 2023 at our institute. We reviewed the comprehensive surgical outcomes, including operative procedures, intraoperative findings, and postoperative morbidities. Overall survival (OS) was calculated using a Kaplan-Meier estimation.</p><p><strong>Results: </strong>The initial clinical stage before medical treatment (c-stage) was stage III in eight patients, stage IV in five patients, and one patient had postoperative lung cancer recurrence. The indications for surgery were as follows: local control for relapse or residual tumor in ten patients and discontinuation of systemic therapy because of treatment-related complications in four patients. The surgical modes were segmentectomy (n = 1), lobectomy (n = 4), bilobectomy (n = 3), pneumonectomy (n = 6), and bronchoplasty (n = 7). Grade 3 or higher postoperative morbidities were observed in six patients, including only one case of 90-day mortality.</p><p><strong>Conclusions: </strong>Our series demonstrated that the surgical outcome of salvage extended surgery after ICI therapy may be positive with careful selection of the procedure and indication.</p>","PeriodicalId":22163,"journal":{"name":"Surgery Today","volume":" ","pages":"917-926"},"PeriodicalIF":1.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140190106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The world's first clinical cardiac xenotransplantation, using a genetically engineered pig heart with 10 gene modifications, prolonged the life of a 57-year-old man with no other life-saving options, by 60 days. It is foreseeable that xenotransplantation will be introduced in clinical practice in the United States. However, little clinical or regulatory progress has been made in the field of xenotransplantation in Japan in recent years. Japan seems to be heading toward a "device lag", and the over-importation of medical devices and technology in the medical field is becoming problematic. In this review, we discuss the concept of pig-heart xenotransplantation, including the pathobiological aspects related to immune rejection, coagulation dysregulation, and detrimental heart overgrowth, as well as genetic modification strategies in pigs to prevent or minimize these problems. Moreover, we summarize the necessity for and current status of xenotransplantation worldwide, and future prospects in Japan, with the aim of initiating xenotransplantation in Japan using genetically modified pigs without a global delay. It is imperative that this study prompts the initiation of preclinical xenotransplantation research using non-human primates and leads to clinical studies.
{"title":"How should cardiac xenotransplantation be initiated in Japan?","authors":"Shunsuke Saito, Shuji Miyagawa, Takuji Kawamura, Daisuke Yoshioka, Masashi Kawamura, Ai Kawamura, Yusuke Misumi, Takura Taguchi, Takashi Yamauchi, Shigeru Miyagawa","doi":"10.1007/s00595-024-02861-7","DOIUrl":"10.1007/s00595-024-02861-7","url":null,"abstract":"<p><p>The world's first clinical cardiac xenotransplantation, using a genetically engineered pig heart with 10 gene modifications, prolonged the life of a 57-year-old man with no other life-saving options, by 60 days. It is foreseeable that xenotransplantation will be introduced in clinical practice in the United States. However, little clinical or regulatory progress has been made in the field of xenotransplantation in Japan in recent years. Japan seems to be heading toward a \"device lag\", and the over-importation of medical devices and technology in the medical field is becoming problematic. In this review, we discuss the concept of pig-heart xenotransplantation, including the pathobiological aspects related to immune rejection, coagulation dysregulation, and detrimental heart overgrowth, as well as genetic modification strategies in pigs to prevent or minimize these problems. Moreover, we summarize the necessity for and current status of xenotransplantation worldwide, and future prospects in Japan, with the aim of initiating xenotransplantation in Japan using genetically modified pigs without a global delay. It is imperative that this study prompts the initiation of preclinical xenotransplantation research using non-human primates and leads to clinical studies.</p>","PeriodicalId":22163,"journal":{"name":"Surgery Today","volume":" ","pages":"829-838"},"PeriodicalIF":1.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11266268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140908812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-01Epub Date: 2024-02-29DOI: 10.1007/s00595-024-02800-6
Mustafa Bektaş, Jaime Ken Pereira, Freek Daams, Donald L van der Peet
ChatGPT has brought about a new era of digital health, as this model has become prominent and been rapidly developing since its release. ChatGPT may be able to facilitate improvements in surgery as well; however, the influence of ChatGPT on surgery is largely unknown at present. Therefore, the present study reports on the current applications of ChatGPT in the field of surgery, evaluating its workflow, practical implementations, limitations, and future perspectives. A literature search was performed using the PubMed and Embase databases. The initial search was performed from its inception until July 2023. This study revealed that ChatGPT has promising capabilities in areas of surgical research, education, training, and practice. In daily practice, surgeons and surgical residents can be aided in performing logistics and administrative tasks, and patients can be more efficiently informed about the details of their condition. However, priority should be given to establishing proper policies and protocols to ensure the safe and reliable use of this model.
{"title":"ChatGPT in surgery: a revolutionary innovation?","authors":"Mustafa Bektaş, Jaime Ken Pereira, Freek Daams, Donald L van der Peet","doi":"10.1007/s00595-024-02800-6","DOIUrl":"10.1007/s00595-024-02800-6","url":null,"abstract":"<p><p>ChatGPT has brought about a new era of digital health, as this model has become prominent and been rapidly developing since its release. ChatGPT may be able to facilitate improvements in surgery as well; however, the influence of ChatGPT on surgery is largely unknown at present. Therefore, the present study reports on the current applications of ChatGPT in the field of surgery, evaluating its workflow, practical implementations, limitations, and future perspectives. A literature search was performed using the PubMed and Embase databases. The initial search was performed from its inception until July 2023. This study revealed that ChatGPT has promising capabilities in areas of surgical research, education, training, and practice. In daily practice, surgeons and surgical residents can be aided in performing logistics and administrative tasks, and patients can be more efficiently informed about the details of their condition. However, priority should be given to establishing proper policies and protocols to ensure the safe and reliable use of this model.</p>","PeriodicalId":22163,"journal":{"name":"Surgery Today","volume":" ","pages":"964-971"},"PeriodicalIF":1.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11266448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139991204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Owing to the high objective response rate of atezolizumab plus bevacizumab (Atez/Bev) for hepatocellular carcinoma (HCC), the concept of sequential conversion to local treatment has recently become mainstream. The conversion concept is mainly applied to Barcelona Clinic for Liver Cancer (BCLC) stage B cases, and radiotherapy is rarely considered as a conversion local treatment. We herein report three patients who were treated with the novel concept of "sequential particle radiotherapy," consisting of Atez/Bev therapy followed by particle radiotherapy (PRT) for HCC with advanced portal vein tumor thrombus (Vp3/4 PVTT). All patients achieved partial response radiologically and were switched to PRT. All patients were recurrence free at 1 year after the introduction of Atez/Bev therapy without any additional treatment. This upcoming combination strategy includes the advocacy of sequential concepts for BCLC stage C cases and the introduction of PRT as a local treatment after Atez/Bev.
由于阿特珠单抗联合贝伐单抗(Atez/Bev)治疗肝细胞癌(HCC)的客观反应率很高,最近,依次转换为局部治疗的概念已成为主流。这种转换概念主要适用于巴塞罗那肝癌诊所(BCLC)的 B 期病例,而放疗很少被视为一种转换局部治疗的方法。我们在此报告了三例采用 "序贯粒子放疗 "这一新理念治疗晚期门静脉瘤栓(Vp3/4 PVTT)HCC的患者,包括先接受Atez/Bev治疗,然后再接受粒子放疗(PRT)。所有患者均在放射学上获得部分反应,并转为 PRT 治疗。所有患者在接受 Atez/Bev 治疗 1 年后均无复发,且未接受任何其他治疗。即将推出的这一组合策略包括倡导对 BCLC C 期病例采用序贯概念,并在 Atez/Bev 治疗后引入 PRT 作为局部治疗。
{"title":"Novel concept of \"sequential particle radiotherapy\" with atezolizumab plus bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus.","authors":"Shohei Komatsu, Kazuki Terashima, Nobuaki Ishihara, Yoshiro Matsuo, Masahiro Kido, Hiroaki Yanagimoto, Hirochika Toyama, Sunao Tokumaru, Tomoaki Okimoto, Takumi Fukumoto","doi":"10.1007/s00595-024-02805-1","DOIUrl":"10.1007/s00595-024-02805-1","url":null,"abstract":"<p><p>Owing to the high objective response rate of atezolizumab plus bevacizumab (Atez/Bev) for hepatocellular carcinoma (HCC), the concept of sequential conversion to local treatment has recently become mainstream. The conversion concept is mainly applied to Barcelona Clinic for Liver Cancer (BCLC) stage B cases, and radiotherapy is rarely considered as a conversion local treatment. We herein report three patients who were treated with the novel concept of \"sequential particle radiotherapy,\" consisting of Atez/Bev therapy followed by particle radiotherapy (PRT) for HCC with advanced portal vein tumor thrombus (Vp3/4 PVTT). All patients achieved partial response radiologically and were switched to PRT. All patients were recurrence free at 1 year after the introduction of Atez/Bev therapy without any additional treatment. This upcoming combination strategy includes the advocacy of sequential concepts for BCLC stage C cases and the introduction of PRT as a local treatment after Atez/Bev.</p>","PeriodicalId":22163,"journal":{"name":"Surgery Today","volume":" ","pages":"972-976"},"PeriodicalIF":1.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140022586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-01Epub Date: 2024-03-12DOI: 10.1007/s00595-024-02796-z
Yuko Homma, Toshiki Mimura, Koji Koinuma, Hisanaga Horie, Naohiro Sata
Purpose: Low anterior resection syndrome (LARS) causes devastating symptoms and impairs the quality of life (QOL). This study investigated the incidence and risk factors of LARS and their association with the QOL in patients with lower rectal tumors.
Methods: Patients who underwent anus-preserving surgery for lower rectal tumors between 2014 and 2019 and who had anal defecation between 2020 and 2021 were surveyed. The LARS score measured severity, and the QOL was evaluated using the Japanese version of the Fecal Incontinence Quality-of-Life Scale (JFIQL). The primary endpoint was the incidence of Major LARS, and the secondary endpoints were risk factors and association with the JFIQL.
Results: Of 107 eligible patients, 82 (76.6%) completed the LARS survey. The incidence of Major LARS was 48%. Independent risk factors included neoadjuvant chemoradiotherapy (CRT) and a short interval (< 24 months after surgery; odds ratio, 4.6; 95% confidence interval: 1.1-19, both). The LARS score was moderately correlated with the JFIQL generic score (correlation coefficient: - 0.54). The JFIQL scores were significantly worse in the Minor and Major LARS groups than in the No LARS group.
Conclusions: Major LARS was found in 48% of lower rectal tumors, and independent risk factors include neoadjuvant CRT and a short interval. The QOL was significantly impaired in patients with both Minor and Major LARS.
目的:低位前切除综合征(LARS)会导致破坏性症状并损害生活质量(QOL)。本研究调查了直肠下部肿瘤患者 LARS 的发病率、风险因素及其与 QOL 的关系:方法:调查了2014年至2019年期间因直肠下端肿瘤接受保肛手术的患者,以及2020年至2021年期间有肛门排便的患者。LARS评分衡量严重程度,QOL则使用日文版大便失禁生活质量量表(JFIQL)进行评估。主要终点是重度 LARS 的发生率,次要终点是风险因素以及与 JFIQL 的关系:在 107 名符合条件的患者中,82 人(76.6%)完成了 LARS 调查。重大 LARS 的发生率为 48%。独立的风险因素包括新辅助化放疗(CRT)和较短的间隔期(结论:48%的患者发现了严重 LARS:48%的直肠下段肿瘤患者出现严重LARS,独立风险因素包括新辅助CRT和间隔时间短。轻度和重度 LARS 患者的 QOL 均明显受损。
{"title":"Incidence of low anterior resection syndrome and its association with the quality of life in patients with lower rectal tumors.","authors":"Yuko Homma, Toshiki Mimura, Koji Koinuma, Hisanaga Horie, Naohiro Sata","doi":"10.1007/s00595-024-02796-z","DOIUrl":"10.1007/s00595-024-02796-z","url":null,"abstract":"<p><strong>Purpose: </strong>Low anterior resection syndrome (LARS) causes devastating symptoms and impairs the quality of life (QOL). This study investigated the incidence and risk factors of LARS and their association with the QOL in patients with lower rectal tumors.</p><p><strong>Methods: </strong>Patients who underwent anus-preserving surgery for lower rectal tumors between 2014 and 2019 and who had anal defecation between 2020 and 2021 were surveyed. The LARS score measured severity, and the QOL was evaluated using the Japanese version of the Fecal Incontinence Quality-of-Life Scale (JFIQL). The primary endpoint was the incidence of Major LARS, and the secondary endpoints were risk factors and association with the JFIQL.</p><p><strong>Results: </strong>Of 107 eligible patients, 82 (76.6%) completed the LARS survey. The incidence of Major LARS was 48%. Independent risk factors included neoadjuvant chemoradiotherapy (CRT) and a short interval (< 24 months after surgery; odds ratio, 4.6; 95% confidence interval: 1.1-19, both). The LARS score was moderately correlated with the JFIQL generic score (correlation coefficient: - 0.54). The JFIQL scores were significantly worse in the Minor and Major LARS groups than in the No LARS group.</p><p><strong>Conclusions: </strong>Major LARS was found in 48% of lower rectal tumors, and independent risk factors include neoadjuvant CRT and a short interval. The QOL was significantly impaired in patients with both Minor and Major LARS.</p>","PeriodicalId":22163,"journal":{"name":"Surgery Today","volume":" ","pages":"857-865"},"PeriodicalIF":1.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140111466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: Saliva is often used as a tool for identifying systemic diseases because of the noninvasive nature of its collection. Moreover, salivary metabolites can be potential predictive factors for postoperative survival. We conducted the present study to establish whether salivary metabolites can function as predictive biomarkers for lung surgery complications.
Methods: Unstimulated salivary samples were collected from 412 patients before lung surgery. Salivary metabolites were analyzed comprehensively by capillary electrophoresis mass spectrometry. Clinical data with the discriminatory ability of biomarkers were assessed to predict lung surgery complications using multivariate logistic regression analysis. The primary endpoint was the risk factors for postoperative complications of Clavien-Dindo grade ≥ III.
Results: Postoperative complications of Clavien-Dindo grade ≥ III developed in 36 patients (8.7%). There was no postoperative 30-day mortality. Male sex (odds ratio [OR], 3.852; 95% confidence interval CI 1.455-10.199; p = 0.007) and salivary gamma-butyrobetaine (OR, 0.809; 95% CI 0.694-0.943; p = 0.007) were identified as significant risk factors for postoperative complications of Clavien-Dindo grade ≥ III.
Conclusion: Salivary metabolites are potential noninvasive biomarkers for predicting postoperative complications of lung surgery.
目的:由于唾液采集的无创性,唾液经常被用作识别全身性疾病的工具。此外,唾液代谢物还是术后存活率的潜在预测因素。本研究旨在确定唾液代谢物是否可作为肺部手术并发症的预测性生物标志物:方法:我们收集了 412 名肺部手术前患者的未受刺激唾液样本。采用毛细管电泳质谱法对唾液代谢物进行了全面分析。利用多变量逻辑回归分析评估了临床数据与生物标志物的鉴别能力,以预测肺部手术并发症。主要终点是Clavien-Dindo≥III级术后并发症的风险因素:结果:36 例患者(8.7%)术后出现 Clavien-Dindo ≥ III 级并发症。术后 30 天无死亡病例。男性(几率比 [OR],3.852;95% 置信区间 CI 1.455-10.199;P = 0.007)和唾液中的γ-丁卡因(OR,0.809;95% 置信区间 CI 0.694-0.943;P = 0.007)被确定为克拉维恩-丁度≥ III 级术后并发症的重要风险因素:唾液代谢物是预测肺部手术术后并发症的潜在无创生物标志物。
{"title":"Salivary metabolites as potential predictive biomarkers for lung surgery complications: a retrospective cross-sectional study.","authors":"Satoshi Takamori, Shigeo Ishikawa, Kaito Sato, Hikaru Watanabe, Jun Suzuki, Hiroyuki Oizumi, Satoshi Shiono, Tetsuro Uchida, Naoki Okuyama, Kaoru Edamatsu, Mitsuyoshi Iino, Masahiro Sugimoto","doi":"10.1007/s00595-024-02794-1","DOIUrl":"10.1007/s00595-024-02794-1","url":null,"abstract":"<p><strong>Purpose: </strong>Saliva is often used as a tool for identifying systemic diseases because of the noninvasive nature of its collection. Moreover, salivary metabolites can be potential predictive factors for postoperative survival. We conducted the present study to establish whether salivary metabolites can function as predictive biomarkers for lung surgery complications.</p><p><strong>Methods: </strong>Unstimulated salivary samples were collected from 412 patients before lung surgery. Salivary metabolites were analyzed comprehensively by capillary electrophoresis mass spectrometry. Clinical data with the discriminatory ability of biomarkers were assessed to predict lung surgery complications using multivariate logistic regression analysis. The primary endpoint was the risk factors for postoperative complications of Clavien-Dindo grade ≥ III.</p><p><strong>Results: </strong>Postoperative complications of Clavien-Dindo grade ≥ III developed in 36 patients (8.7%). There was no postoperative 30-day mortality. Male sex (odds ratio [OR], 3.852; 95% confidence interval CI 1.455-10.199; p = 0.007) and salivary gamma-butyrobetaine (OR, 0.809; 95% CI 0.694-0.943; p = 0.007) were identified as significant risk factors for postoperative complications of Clavien-Dindo grade ≥ III.</p><p><strong>Conclusion: </strong>Salivary metabolites are potential noninvasive biomarkers for predicting postoperative complications of lung surgery.</p>","PeriodicalId":22163,"journal":{"name":"Surgery Today","volume":" ","pages":"866-873"},"PeriodicalIF":1.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139736205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-01Epub Date: 2024-03-15DOI: 10.1007/s00595-024-02813-1
Naoko Fukushima, Takahiro Masuda, Kazuto Tsuboi, Keita Takahashi, Masami Yuda, Muneharu Fujisaki, Toru Ikegami, Fumiaki Yano, Ken Eto
Purpose: Systemic inflammatory response markers are reported to be prognostic for patients with cancer. The C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index has been established as an immuno-nutritional scoring system. The aim of this study was to clarify the impact of the preoperative CALLY index on the outcome of patients undergoing gastrectomy for gastric cancer.
Methods: We analyzed the data of 826 patients who underwent gastrectomy for stage I, II, or III gastric cancer between 2010 and 2017. The CALLY index was defined as (albumin × lymphocyte)/(CRP × 104).
Results: The cut-off of the CALLY index was 2. The 147 patients with a preoperative CALLY index < 2 had significantly worse overall survival (OS) and relapse-free survival (RFS) than those with a CALLY index ≥ 2 (P < 0.01, P < 0.01, respectively). Multivariate analysis identified that a CALLY index < 2 (P = 0.02), intraoperative blood loss (P < 0.01), and stage II or III disease (P < 0.01) were independent and significant predictors of worse RFS. A CALLY index < 2 (P = 0.01), intraoperative blood loss (P < 0.01), postoperative complications (P = 0.02), and stage II or III disease (P < 0.01) were independent and significant predictors of worse OS.
Conclusion: The preoperative CALLY index was independently associated with a poor prognosis for patients after gastrectomy for gastric cancer.
{"title":"Prognostic significance of the preoperative C-reactive protein-albumin-lymphocyte (CALLY) index on outcomes after gastrectomy for gastric cancer.","authors":"Naoko Fukushima, Takahiro Masuda, Kazuto Tsuboi, Keita Takahashi, Masami Yuda, Muneharu Fujisaki, Toru Ikegami, Fumiaki Yano, Ken Eto","doi":"10.1007/s00595-024-02813-1","DOIUrl":"10.1007/s00595-024-02813-1","url":null,"abstract":"<p><strong>Purpose: </strong>Systemic inflammatory response markers are reported to be prognostic for patients with cancer. The C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index has been established as an immuno-nutritional scoring system. The aim of this study was to clarify the impact of the preoperative CALLY index on the outcome of patients undergoing gastrectomy for gastric cancer.</p><p><strong>Methods: </strong>We analyzed the data of 826 patients who underwent gastrectomy for stage I, II, or III gastric cancer between 2010 and 2017. The CALLY index was defined as (albumin × lymphocyte)/(CRP × 10<sup>4</sup>).</p><p><strong>Results: </strong>The cut-off of the CALLY index was 2. The 147 patients with a preoperative CALLY index < 2 had significantly worse overall survival (OS) and relapse-free survival (RFS) than those with a CALLY index ≥ 2 (P < 0.01, P < 0.01, respectively). Multivariate analysis identified that a CALLY index < 2 (P = 0.02), intraoperative blood loss (P < 0.01), and stage II or III disease (P < 0.01) were independent and significant predictors of worse RFS. A CALLY index < 2 (P = 0.01), intraoperative blood loss (P < 0.01), postoperative complications (P = 0.02), and stage II or III disease (P < 0.01) were independent and significant predictors of worse OS.</p><p><strong>Conclusion: </strong>The preoperative CALLY index was independently associated with a poor prognosis for patients after gastrectomy for gastric cancer.</p>","PeriodicalId":22163,"journal":{"name":"Surgery Today","volume":" ","pages":"943-952"},"PeriodicalIF":1.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140140857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To investigate the treatment outcomes of patients with non-occlusive mesenteric ischemia (NOMI) at our institution, we focused on their post-treatment return to social activities.
Methods: This study included patients with suspected NOMI who were referred to our department between 2011 and 2023. In-hospital mortality was also investigated as a prognostic factor. The Glasgow-Pittsburgh Outcome Categories (GPOC) score was used to evaluate the return to social activities. The relationship between in-hospital mortality and GPOC scores and patient background and treatment factors was examined.
Results: Eighty-two patients were included in the study. Among them, 54 (65.9%) died during hospitalization. Only 9 patients (11%) returned to their social activities. In the multivariate analysis, non-surgical management was found to be the only independent factor for in-hospital mortality. Positive portal venous gas on computed tomography, no open abdomen, no pre-onset catecholamine administration, platelet count < 100,000/µL, lactate level < 5 mmol/L, APTT < 46 s, and Sequential Organ Failure Assessment score < 11 were factors significantly associated with an increased likelihood of return to social activities.
Conclusion: This is the first study to assess the post-treatment return to social activities among patients with NOMI. Our findings highlight the concerning reality that survivors may face prolonged dependence on medical care.
{"title":"Treatment outcomes in non-occlusive mesenteric ischemia and post-treatment return to social activities.","authors":"Gaku Ohira, Koichi Hayano, Toru Tochigi, Tetsuro Maruyama, Takeshi Toyozumi, Yoshihiro Kurata, Michihiro Maruyama, Satoko Arai, Taka-Aki Nakada, Hisahiro Matsubara","doi":"10.1007/s00595-024-02909-8","DOIUrl":"https://doi.org/10.1007/s00595-024-02909-8","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the treatment outcomes of patients with non-occlusive mesenteric ischemia (NOMI) at our institution, we focused on their post-treatment return to social activities.</p><p><strong>Methods: </strong>This study included patients with suspected NOMI who were referred to our department between 2011 and 2023. In-hospital mortality was also investigated as a prognostic factor. The Glasgow-Pittsburgh Outcome Categories (GPOC) score was used to evaluate the return to social activities. The relationship between in-hospital mortality and GPOC scores and patient background and treatment factors was examined.</p><p><strong>Results: </strong>Eighty-two patients were included in the study. Among them, 54 (65.9%) died during hospitalization. Only 9 patients (11%) returned to their social activities. In the multivariate analysis, non-surgical management was found to be the only independent factor for in-hospital mortality. Positive portal venous gas on computed tomography, no open abdomen, no pre-onset catecholamine administration, platelet count < 100,000/µL, lactate level < 5 mmol/L, APTT < 46 s, and Sequential Organ Failure Assessment score < 11 were factors significantly associated with an increased likelihood of return to social activities.</p><p><strong>Conclusion: </strong>This is the first study to assess the post-treatment return to social activities among patients with NOMI. Our findings highlight the concerning reality that survivors may face prolonged dependence on medical care.</p>","PeriodicalId":22163,"journal":{"name":"Surgery Today","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}